No Data
No Data
Tonix Pharmaceuticals Achieves Key Milestone With FDA Review Timeline for Innovative Fibromyalgia Treatment | NASDAQ:TNXP
Tonix Pharmaceuticals Announces PDUFA Goal Date Of August 15, 2025, For FDA Decision On U.S. Marketing Approval For TNX-102 SL For Fibromyalgia; NDA Based On Two Statistically Significant Phase 3 Studies Of TNX-102 SL For The Management Of...
Express News | Tonix Pharmaceuticals Announces Pdufa Goal Date of August 15, 2025, for FDA Decision on U.S. Marketing Approval for Tnx-102 Sl for Fibromyalgia
Express News | Tonix Pharmaceuticals Holding Corp - Increases Maximum Aggregate Offering Price to $250 Million
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Why Corvus Pharmaceuticals Shares Are Trading Higher By Around 22%; Here Are 20 Stocks Moving Premarket
No Data